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ABSTRACT 
Background: Lupeol is a dietary triterpene, possesses numerous biological activities. Lupeol is currently under development for chemotherapy 
and chemoprevention. The aim of present study was to determine the potential inhibitory effect of Lupeol on cytochrome P450 (CYP3A4 and 
CYP2C9 isozymes) activities in human liver microsomes (HLM). 
Methods:  The inhibition studies were conducted using testosterone 6β-hydroxylase (CYP3A4), and diclofenac 4’-hydroxylase (CYP2C9) activity 
assay using positive control Ketoconazole and Sulphaphenazole, respectively. Inhibition study was performed by incubating Lupeol (0 to 20 μM) 
with human liver microsomes, and the metabolite formation was analyzed by liquid chromatography-tandem mass spectrometry (LC-MS/MS). 
Results: Luepol did not inhibit CYP3A4 and CYP2C9 isozymes mediated activities in human liver microsomes up to a maximum tested 
concentration of 20µM based on solubility under tested invitro conditions.  
Conclusions: Lupeol is not an inhibitor of the CYP3A4 and CYP2C9 isozymes. IC50 is greater than the highest tested concentration as well as 
physiological concentration, where effect was measured with confidence. Therefore, clinically relevant pharmacokinetic herb-drug interactions 
are unlikely to occur between Lupeol and co-administered substrates of these CYP isozymes. Looking at the spectrum of biological activities and 
CYP inhibition potential of Lupeol; Lupeol can be used as adjuvant/ chemotherapy agent/ chemopreventive agent in therapy. 
Keywords: Lupeol, HLM, CYP3A4 and CYP2C9, Inhibition, herb–drug interactions 
 
Article Info: Received 07 Feb 2019;     Review Completed 08 March 2019;     Accepted 10 March 2019;     Available online 15 March 2019 
Cite this article as: 
Khatal L, More H, In-vitro assessment of CYP3A4 and CYP2C9 inhibition potential of Lupeol using human liver microsomes, 
Journal of Drug Delivery and Therapeutics. 2019; 9(2):231-236     http://dx.doi.org/10.22270/jddt.v9i2.2562                                                          
*Address for Correspondence:  
Laxman Khatal, Bharati Vidyapeeth College of Pharmacy, Kolhapur, Near Chitranagri, Kolhapur-416013, Maharashtra, India 
 
 
1.  INTRODUCTION 
Lupeol [Lup-20(29)-en-3β-ol] (Figure 1) is a dietary 
triterpene, also known as clerodol, fagarsterol, and lupenol.  
Lupeol is common constituent of grape, cocoa butter, 
hazelnut, olive oil, white cabbage, mango pulp, and a variety 
of therapeutic plants. Lupeol exhibits multiple 
pharmacological properties that include antiarthritic, 
antioxidant, anti-inflammatory, antitumor, antimalarial 
activity, antimicrobial, antiprotozoal, cancer 
chemopreventive and cardio-hepato protective 1-3.  Lupeol 
possesses anti-cancer activity against various cancers that 
include melanoma, prostate, head, and neck cancer. Activity 
of topoisomerase II (a known target for anticancer 
chemotherapy) is inhibited by Lupeol.  Lupeol is currently 
under development for chemotherapy as well as 
chemoprevention 1. 
Herbal medicines are increasingly being used as alternative 
medicines worldwide over the last few decades. Most of the 
herbal medicines are non-toxic, safe in nature, and easier to 
obtain, hence preferred over allopathic medicines 4. As a 
result, it is very likely that some patients will take herbal 
medicines concomitantly with conventional prescription 
medications. This may lead to unwanted adverse effects 
produced by herbal-drug interactions 5. Serious questions 
concerning the safety, quality, and efficacy of these products 
has raised due to widespread use of herbal medicines. Risk 
for herb-drug interactions has increased as more than 80% 
of worldwide population makes use of traditional medicines, 
often in combination with prescription drugs 6-8. 
 
Figure 1: Structure of Lupeol 
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Cytochrome P450 (CYP) is a superfamily of mixed function 
oxidases that are responsible for the metabolism of many 
drugs (~ 80%) including anticancer agents. CYP3A4 and 
CYP2C9 isozymes are responsible for the metabolism of 
more than 60% of all prescribed drugs.  When patients 
receive several medications concurrently, unwanted and life-
threatening effects can result from the competition for the 
same drug-metabolizing enzyme affecting the  blood levels of 
those drugs, leading to toxicity 9-12. Numbers of new chemical 
entities and marketed drugs have been withdrawn from the 
pharmaceutical market because of toxicity issue 13. Cancer 
patients would seem to be significantly at high risk, because 
CYP3A4 metabolizes a large number of anticancer drugs and 
patients are generally prescribed other medications to 
relieve symptoms (e.g., analgesics) and side-effects (e.g., 
antidiarrheals and antiemetics) and to treat comorbidities 14.  
For a new molecular entity, it is mandatory to assess its 
likely inhibitory or inductive effects at preclinical drug 
discovery research level as recommended by the U.S. Food 
and Drug Administration and the EMEA guidelines 15-16. 
Lupeol possesses several biological activities. Hence, it is 
likely that Lupeol will be administered with other 
therapeutic agents in clinical settings. This study was 
conducted to evaluate the potential of lupeol for significant 
metabolic-based interactions in human liver microsomal 
enzymes. Seervi et. al. 17 clearly states that further studies of 
lupeol on human liver microsomes will help in confirming 
CYP-mediated interaction potential in human beings. Peak 
plasma concentration of lupeol upon administration of 
200mg/kg one time intra peritoneal dose is 5.22 µM at 8 hrs 
in mice 2.  The concentrations of Lupeol employed in this 
study based on solubility of Lupeol span and exceed the Cmax 
reported by Siddique et. al. 2. 
2. MATERIALS AND METHODS 
2.1 Chemicals and reagents 
Lupeol (purity 99 %) was purchased from Natural Remedies 
Private Limited, Bangalore, India. Ketoconazole, 
Sulfaphenazole, Diclofenac, and Testosterone were received 
as gift Samples from CIPLA (Patalganga Panvel, Maharashtra, 
India). Corticosterone, Hydroxy- Diclofenac D4, Hydroxy-
Testosterone and Hydroxy-Diclofenac were obtained from 
CDRI (Luckhnow, Delhi, India). Human liver microsomes 
were procured from Sekisui XenoTech, LLC (Kansas City, 
North America). Nicotinamide adenine dinucleotide 
phosphate (NADPH), formic acid 98% (MS grade), Potassium 
phosphate monobasic and Potassium phosphate dibasic 
were purchased from Sigma-Aldrich; Fluka (St. Louis, MO, 
USA). HPLC- grade acetonitrile and dimethyl sulphoxide 
(DMSO) were obtained from Merck (Mumbai, India). All 
other chemicals and reagents were of analytical grade and 
procured from commercial suppliers in India. 
2.2 LC-MS/MS Instrument and Conditions 
Separation was performed on HPLC System (Shimadzu 
Corporation, Kyoto, Japan). HPLC system equipped with LC-
20AD binary pump, a DGU20A degasser, an SIL-HTC auto-
sampler and a CTO-20A thermo-stated column oven 
maintained at 40°C during analysis. Optimized 
Chromatographic conditions are mentioned in table 1. 
 
Table 1: Optimized chromatographic conditions employed in analysis 
Parameter CYP3A4 Inhibition Assay CYP 2C9 Inhibition Assay 
Mobile phase A 0.1% Formic acid 10 mM Ammonium Formate with 0.1% formic acid 
Mobile phase B Acetonitrile Acetonitrile 
Flow rate 0.8ml/min 0.8ml/min 
Run time 5.0 min 5.7 min 
Column Thermo Scientific, Acclaim polar advantage,  
4.6*50mm, 3.5µm 
Agilent, Zorbax SB-CN,  4.6*50mm, 3.5µm 
Retention time 6-β-hydroxy testosterone: 3.08 min 4-OH-diclofenac: 3.10 min 
Corticosterone: 3.24 min 4-OH-diclofenac-D4: 3.10 min 
Gradient 
programme 
Time (min) % B 
0.5 20 
2.0 95 
3.5 95 
3.6 20 
5.0 STOP 
 
Time (min) % B 
0.5 20 
2.5 90 
3.7 90 
3.8 20 
5.7 STOP 
 
 
Mass spectrometric detection was performed on an API-
4000 triple quadrupole instrument from Sciex (Applied 
Biosystems, Foster City, CA, USA) using MRM (Multiple 
Reaction Monitoring) mode. Optimized electrospray ion 
source parameters are mentioned in Table 2. Optimized 
multiple reaction monitoring (MRM) parameters for analyte 
and internal standard (IS) are mentioned in Table 3. Data 
acquisition and analysis were performed using the analyst 
software version 1.6 (Applied Biosystems, Foster City, CA, 
USA). 
 
Table 2: Optimized source parameters employed in analysis 
Source Parameter CYP3A4 Inhibition Assay CYP 2C9 Inhibition Assay 
Ionization mode ESI Positive ESI Negative 
Curtain gas (psi) 20 20 
Collision-activated dissociation (CAD) gas (units) 6 6 
Gas-1(psi) 50 50 
Gas-2 (psi) 70 70 
Ion Spray Voltage (V) 5500 -4500 
Ion source temperature (°C) 500 500 
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Table 3: Optimized Multiple Reaction Monitoring (MRM) parameters employed in analysis 
Name of Metabolite/ 
Internal Standard 
Parent ion (m/z)  
(Q1) 
Daughter ion (m/z) 
(Q3) 
DP EP CE CXP 
CYP3A4 Inhibition Assay - Positive polarity 
6-β-hydroxy testosterone 305.20 287.5, 269.70 61 10 19,18 5 
Corticosterone* 347.18 121.20, 329.30 45 10 33,21 4 
CYP 2C9 Inhibition Assay - Negative polarity 
4-OH-diclofenac 310.10 265.90 -45 -10 -20 -15 
4-OH-diclofenac-D4* 314.03 269.90, 234.10 -50 -10 -18,-14 -19,-5 
*used as internal Standard; DP: declustering potential (V); EP: entrance potential (V); CE: collision energy (V) and CXP: collision cell exit potential (V) 
 
2.3 Microsomal incubation 
Stock solution of Lupeol and all other substrates were 
prepared in DMSO. Stock solutions of positive controls were 
prepared in acetonitrile; further dilutions were prepared in 
acetonitrile: DMSO (80:20 v/v). Testosterone and Diclofenac 
were used as selective probe substrates for CYP3A4 and 
CYP2C9, respectively. Testosterone 6β-hydroxylase and 
diclofenac 4’-hydroxylase assays were standardized with 
modification of reported methods 18-24. 
Standardization of incubation conditions 
Incubation time and protein concentration were 
standardized in the human liver microsomes. The Km values 
for each of the respective marker substrates were 
determined using a range of substrate concentrations with 
optimized protein concentration and time.  
2.4 Data analysis 
The standard selective inhibitors, namely, sulfaphenazole, 
and ketoconazole were used for CYP2C9, and CYP3A4 
inhibition, respectively. The IC50 values of the inhibitors 
were determined graphically (plot of the logarithm of 
inhibitor concentration versus the percentage of enzyme 
activity) by fitting a non-linear regression constrain (2PL) of 
Bottom constant equal to ‘’0’’ and Top constant equal to 
‘’100’’ by Graph Pad Prism 6.0 (GraphPad software Inc., CA, 
USA). Area ratio (Metabolite/IS) and inhibitor concentration 
in µM is used to calculate the IC50 by Graph Pad Prism 6.0. 
3. RESULTS 
3.1 Standardization of incubation conditions 
Incubation conditions were standardized by incubating the 
respective probe substrates with different protein 
concentrations (0.10–1.0 mg/mL) of microsomes and by 
terminating the reactions at different time intervals (0–60 
min). The optimum incubation time and protein 
concentration was selected on the basis of linear metabolite 
formation. For the determination of Km, different 
concentrations of CYP450 substrates were incubated with 
the standardized protein concentrations. Km values were 
determined by the Eadie-Hofstee plot and Lineweaver-Burk 
plot and final optimized incubation conditions are 
mentioned in Table 4. 
 
 
Table 4: Standardized Incubation conditions 
Parameter CYP 3A4 Inhibition assay reaction 
conditions 
CYP 2C9 Inhibition assay reaction  
conditions 
Buffer 50mM Potassium Phosphate Buffer (pH 7.4) 50mM Potassium Phosphate Buffer (pH 7.4) 
Substrate  conc. Km Testosterone, 65 µM Diclofenac, 10 µM 
Positive control conc. used 
(µM) 
Ketoconazole: 
1,0.5,0.25,0.062,0.031,0.016,0.008,0.004,0.00
2,0.001,0 
Sulfaphenazole: 
20,10,5,2.5,1.25,0.625,0.312,0.156, 
0.078,0.039,0.019,0 
Lupeol conc. used  (µM) 20,10,5,2.5,1.25,0.625,0.312,0.156,0.078,0.03
9,0.019,0 
20,10,5,2.5,1.25,0.625,0.312,0.156, 
0.078,0.039,0.019,0 
Protein (HLM) 0.15 mg/mL 0.15 mg/mL 
Pre-incubation time and temp 5 min and  37 degree 5 min and  37 degree 
NADPH 2 mM 2 mM 
Final reaction Volume 200 µL 200 µL 
Final Organic content (% v/v) 0.5% (0.4% Acetonitrile + 0.1% DMSO) 0.5% (0.4% Acetonitrile + 0.1% DMSO) 
Incubation time and temp 5 min and  37 degree 5 min and  37 degree 
Metabolite 6-β-hydroxytestosterone 4’-Hydroxydiclofenac 
IS conc. Cotricosterone (1 µM) 4-OH Diclofenac-D4 (1µM) 
After incubation Reaction was terminated by addition of  200 µL of ice cold acetonitrile containing IS, then 
samples were allowed for protein precipitation on ice for 5 min, then vortexed and centrifuged 
at 3000g for 10 min. Supernatants were transferred into 96-well plates for LC–MS/MS 
analysis. 
 
3.2 Inhibitory effect on CYP3A4 and CYP2C9 isozymes/ 
Determination of IC50 
Both positive control inhibitors produced inhibitory effects 
on the respective catalytic activities with IC50 value of 0.029 
µM of Ketoconazole for CYP3A4 and 0.150 µM of 
sulphaphenazole for CYP2C9, observed IC50 values are by 
previous reports 18-19. The compounds were classified as 
potent (IC50 ≤ 10 μM), moderate (IC50 from 10 to 50 μM), or 
weak (IC50 ≥ 50 μM) CYP inhibitors 25. Lupeol did not inhibit 
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CYP2C9 and CYP3A4-mediated activities up to a 20µM 
concentration under the tested in vitro conditions. Figure 2-
5 shows the relationship between inhibitor concentration 
and enzyme activity (enzyme activity was calculated by 
amount of formation of metabolite in presence of different 
concentration of inhibitor). 
 
Figure 2: Log of Ketoconazole concentration (µM) Vs % 
Control (for Isozyme CYP3A4) 
 
Figure 3: Log of Lupeol concentration (µM) Vs % Control 
(for Isozyme CYP3A4) 
 
Figure 4: Log of Sulphaphenazole concentration (µM) Vs 
% Control (for Isozyme CYP2C9) 
 
Figure 5: Log of Lupeol concentration (µM) Vs % Control 
(for Isozyme CYP2C9) 
 
4. DISCUSSION 
Currently, there has been an increase in the use of herbal 
remedies as complementary and alternative medicines along 
with the therapeutics drugs. More than 80% of the 
prescribed drugs are metabolized by CYP enzymes, therefore 
concomitant administrations of herbal and allopathic 
medicines are liable to serious herb-drug interactions 12. The 
major isozymes present in human liver microsomes are 
CYP3A4/5, CYP2C9/19, and CYP1A2 26. There are several 
reported herb-drug interactions involving CYP inhibition, 
such as the components of grapefruit juice interfering with 
the metabolism of terfenadine and nifedipine, garlic with 
saquinavir, etc. 27-28. Upon consideration of above-mentioned 
facts, it becomes imperative to predict herb-drug 
interactions with respect to CYP enzymes in the early drug 
discovery and development era. 
Lupeol is widely distributed triterpenoid present in 
significant amounts in dietary substances and may modulate 
the CYP enzymatic activity. Lupeol exhibits several biological 
activities. Recently, Lupeol was studied in clinical settings for 
its anti-acne effect 29 and non-inflammatory acne lesions 30. 
Lupeol is currently under development for 
chemoprevention, chemotherapy, and also called as ‘magical 
drug’ 31. Therefore, it is likely that Lupeol will be 
administered with other therapeutic agents in clinical 
settings some of which are likely to be CYP3A4 and CYP2C9 
substrates. It is important to understand any potential herb–
drug interactions due to inhibition of these CYP enzymes by 
Lupeol. The results of this study demonstrated that Lupeol 
has very low propensity to interact with CYP isozymes and 
did not inhibit CYP3A4 and CYP2C9 enzymes in human liver 
microsomes. 
Additional experiment of in-vitro metabolic stability study 
(mice, rat and human liver microsomes) and hepatocyte 
stability (mice, rat and human hepatocyte) of lupeol shows 
that lupeol did not undergo phase I or phase II metabolism 
(Data not shown). Hence, CYP enzymes did not play a role in 
metabolic clearance of Lupeol.  Therefore, co-administration 
of any potent CYP inhibitors (e.g., ketoconazole, fluconazole, 
fluoxamine, and quinidine)) or inducers are not likely to 
result in clinically relevant effects on the exposure of Lupeol. 
Peak plasma concentrations of Lupeol reported by Siddique 
et. al. 2 upon administration of 200mg/kg one time intra 
peritoneal dose is 5.22µM in mice, which is considerably 
lower than the highest concentration (20µM) evaluated in 
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this in vitro study. Also, CYP induction study conducted by 
Seervi et al. 17 demonstrated that lupeol did not have any 
induction potential. Therefore, Lupeol is not anticipated to 
precipitate clinically relevant pharmacokinetic herb–drug 
interaction when co-administered with CYP substrates due 
to inhibition or induction. 
5. CONCLUSION 
Lupeol is not an inhibitor of CYP3A4 and CYP2C9 enzymes. 
IC50 is greater than the highest tested concentration as well 
as physiological concentration. Therefore, clinically relevant 
pharmacokinetic herb–drug interactions are unlikely to 
occur between Lupeol and co-administered substrates of 
these CYP isozymes. Looking at the spectrum of biological 
activities and CYP inhibition potential of Lupeol; Lupeol can 
be used as adjuvant/ chemotherapy agent/ chemopreventive 
agent in therapy. 
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